Jabberwocky
Frumious Bandersnatch
thought some of you guys may find some interest in this article - American Medical Association. Use of cannabis for medicinal purposes. Report 3 of the Council on Science and Public Health
Report 3 of the Council on Science and Public Health (I-09)
Use of Cannabis for Medicinal Purposes
(Resolutions 910, I-08; 921, I-08; and 229, A-09)
SUMMARY
Objective. This report: (1) provides a brief historical perspective on the use of cannabis as medicine; (2) examines the current federal and state-based legal envelope relevant to the medical use of cannabis; (3) provides a brief overview of our current understanding of the pharmacology and physiology of the endocannabinoid system; (4) reviews clinical trials on the relative safety and efficacy of smoked cannabis and botanical-based products; and (5) places this information in perspective with respect to the current drug regulatory framework.
Data Sources.
English-language reports on studies using human subjects were selected from a PubMed search of the literature from 2000 to August 2009 using the MeSH terms “marijuana’” “cannabis,” and tetrahydrocannabinol,” or “cannabinoids,” in combination with “drug effects,” “therapeutic use,” “administration & dosage,” “smoking,” “metabolism,” “physiology,” “adverse effects,” and “pharmacology.” Additionally the terms “abuse/epidemiology,” and “receptors, cannabinoid” in combination with “agonists,” or “antagonists & inhibitors” as well as “endocannabinoids,” in combination with “pharmacology,” “physiology,” or “metabolism” were used. Additional articles were identified by manual review of the references cited in these publications. Web sites of the Food and Drug Administration, Drug Enforcement Administration, National Institute on Drug Abuse, Marijuana Policy Project, ProCon.org, and the International Association for Cannabis as Medicine also were searched for relevant resources.
Results.
The cannabis sativa plant contains more than 60 unique structurally related chemicals (phytocannabinoids). Thirteen states have enacted laws to remove state-level criminal penalties for possessing marijuana for qualifying patients, however the federal government refuses to recognize that the cannabis plant has an accepted medical benefit. Despite the public controversy, less than 20 small randomized controlled trials of short duration involving ~300 patients have been conducted over the last 35 years on smoked cannabis. Many others have been conducted on FDA-approved oral preparations of THC and synthetic analogues, and more recently on botanical extracts of cannabis. Federal court cases have upheld the privileges of doctor-patient discussions on the use of cannabis for medicinal purposes but also preserved the right of the federal government to prosecute patients using cannabis for medicinal purposes. Efforts to reschedule marijuana from Schedule I of the Controlled Substances Act have been unsuccessful to date. Disagreements persist about the long term consequences of marijuana use for medicinal purposes.
Conclusions.
Results of short term controlled trials indicate that smoked cannabis reduces neuropathic pain, improves appetite and caloric intake especially in patients with reduced muscle mass, and may relieve spasticity and pain in patients with multiple sclerosis. However, the patchwork of state-based systems that have been established for “medical marijuana” is woefully inadequate in establishing even rudimentary safeguards that normally would be applied to the appropriate clinical use of psychoactive substances. The future of cannabinoid-based medicine lies in the rapidly evolving field of botanical drug substance development, as well as the design of molecules that target various aspects of the endocannabinoid system. To the extent that rescheduling marijuana out of Schedule I will benefit this effort, such a move can be supported.
RECOMMENDATION
The Council on Science and Public Health recommends that Policy H-95.952 be amended by insertion and deletion to read as follows:
H-95.952 Medical Marijuana
(1)
Our American Medical Association (AMA) calls for further adequate and well-controlled 8 studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease.
(2)
Our AMA recommends that marijuana be retained in Schedule I of the Controlled Substances Act pending the outcome of such studies. Our AMA urges that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods. This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product. (New HOD Policy)
(3)
Our AMA urges the National Institutes of Health (NIH) to implement administrative procedures to facilitate grant applications and the conduct of well-designed clinical research into the medical utility of marijuana. This effort should include: a) disseminating specific information for researchers on the development of safeguards for marijuana clinical research protocols and the development of a model informed consent on marijuana for institutional review board evaluation; b) sufficient funding to support such clinical research and access for qualified investigators to adequate supplies of marijuana for clinical research purposes; c) confirming that marijuana of various and consistent strengths and/or placebo will be supplied by the National Institute on Drug Abuse to investigators registered with the Drug Enforcement Agency who are conducting bona fide clinical research studies that receive Food and Drug Administration approval, regardless of whether or not the NIH is the primary source of grant support.
(4) Our AMA believes that the NIH should use its resources and influence to support the development of a smoke free inhaled delivery system for marijuana or delta 9 tetrahydrocannabinol (THC) to reduce the health hazards associated with the combustion and inhalation of marijuana.
(5) (4) Our AMA believes that effective patient care requires the free and unfettered exchange
of information on treatment alternatives and that discussion of these alternatives between
physicians and patients should not subject either party to criminal sanctions. (CSA Rep. 10,
I-97; Modified: CSA Rep. 6, A-01)
Report 3 of the Council on Science and Public Health (I-09)
Use of Cannabis for Medicinal Purposes
(Resolutions 910, I-08; 921, I-08; and 229, A-09)
SUMMARY
Objective. This report: (1) provides a brief historical perspective on the use of cannabis as medicine; (2) examines the current federal and state-based legal envelope relevant to the medical use of cannabis; (3) provides a brief overview of our current understanding of the pharmacology and physiology of the endocannabinoid system; (4) reviews clinical trials on the relative safety and efficacy of smoked cannabis and botanical-based products; and (5) places this information in perspective with respect to the current drug regulatory framework.
Data Sources.
English-language reports on studies using human subjects were selected from a PubMed search of the literature from 2000 to August 2009 using the MeSH terms “marijuana’” “cannabis,” and tetrahydrocannabinol,” or “cannabinoids,” in combination with “drug effects,” “therapeutic use,” “administration & dosage,” “smoking,” “metabolism,” “physiology,” “adverse effects,” and “pharmacology.” Additionally the terms “abuse/epidemiology,” and “receptors, cannabinoid” in combination with “agonists,” or “antagonists & inhibitors” as well as “endocannabinoids,” in combination with “pharmacology,” “physiology,” or “metabolism” were used. Additional articles were identified by manual review of the references cited in these publications. Web sites of the Food and Drug Administration, Drug Enforcement Administration, National Institute on Drug Abuse, Marijuana Policy Project, ProCon.org, and the International Association for Cannabis as Medicine also were searched for relevant resources.
Results.
The cannabis sativa plant contains more than 60 unique structurally related chemicals (phytocannabinoids). Thirteen states have enacted laws to remove state-level criminal penalties for possessing marijuana for qualifying patients, however the federal government refuses to recognize that the cannabis plant has an accepted medical benefit. Despite the public controversy, less than 20 small randomized controlled trials of short duration involving ~300 patients have been conducted over the last 35 years on smoked cannabis. Many others have been conducted on FDA-approved oral preparations of THC and synthetic analogues, and more recently on botanical extracts of cannabis. Federal court cases have upheld the privileges of doctor-patient discussions on the use of cannabis for medicinal purposes but also preserved the right of the federal government to prosecute patients using cannabis for medicinal purposes. Efforts to reschedule marijuana from Schedule I of the Controlled Substances Act have been unsuccessful to date. Disagreements persist about the long term consequences of marijuana use for medicinal purposes.
Conclusions.
Results of short term controlled trials indicate that smoked cannabis reduces neuropathic pain, improves appetite and caloric intake especially in patients with reduced muscle mass, and may relieve spasticity and pain in patients with multiple sclerosis. However, the patchwork of state-based systems that have been established for “medical marijuana” is woefully inadequate in establishing even rudimentary safeguards that normally would be applied to the appropriate clinical use of psychoactive substances. The future of cannabinoid-based medicine lies in the rapidly evolving field of botanical drug substance development, as well as the design of molecules that target various aspects of the endocannabinoid system. To the extent that rescheduling marijuana out of Schedule I will benefit this effort, such a move can be supported.
RECOMMENDATION
The Council on Science and Public Health recommends that Policy H-95.952 be amended by insertion and deletion to read as follows:
H-95.952 Medical Marijuana
(1)
Our American Medical Association (AMA) calls for further adequate and well-controlled 8 studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease.
(2)
Our AMA recommends that marijuana be retained in Schedule I of the Controlled Substances Act pending the outcome of such studies. Our AMA urges that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods. This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product. (New HOD Policy)
(3)
Our AMA urges the National Institutes of Health (NIH) to implement administrative procedures to facilitate grant applications and the conduct of well-designed clinical research into the medical utility of marijuana. This effort should include: a) disseminating specific information for researchers on the development of safeguards for marijuana clinical research protocols and the development of a model informed consent on marijuana for institutional review board evaluation; b) sufficient funding to support such clinical research and access for qualified investigators to adequate supplies of marijuana for clinical research purposes; c) confirming that marijuana of various and consistent strengths and/or placebo will be supplied by the National Institute on Drug Abuse to investigators registered with the Drug Enforcement Agency who are conducting bona fide clinical research studies that receive Food and Drug Administration approval, regardless of whether or not the NIH is the primary source of grant support.
(4) Our AMA believes that the NIH should use its resources and influence to support the development of a smoke free inhaled delivery system for marijuana or delta 9 tetrahydrocannabinol (THC) to reduce the health hazards associated with the combustion and inhalation of marijuana.
(5) (4) Our AMA believes that effective patient care requires the free and unfettered exchange
of information on treatment alternatives and that discussion of these alternatives between
physicians and patients should not subject either party to criminal sanctions. (CSA Rep. 10,
I-97; Modified: CSA Rep. 6, A-01)